The clinical efficacy of venlafaxine in the treatment of depression

Reviews in Contemporary Pharmacotherapy

Volumn 9, Issue 5, 1998, Pages 303-320

  Burnett, Frances E ^a   Dinan, Timothy G ^b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CLOMIPRAMINE; FLUOXETINE; IMIPRAMINE; LITHIUM; MICROSPHERE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; PSYCHOMETRY; SUSTAINED RELEASE FORMULATION; TREATMENT OUTCOME;

EID: 0031819040     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Aguiar L, Derivan AT, for the Venlafaxine XR 209 Study Group. Once-daily venlafaxine extended release (XR) in outpatients with major depression. Presented at the World Congress of Psychiatry, Nice, 23-27 June, 1997.
2. Altamura AC, Montgomery SA. Fluoxetine dose, pharmacokinetics and clinical efficacy. Rev Contemp Pharmacother 1990; 1: 75-81.
3. Andrews JM, Nemeroff CB. Contemporary management of depression. Am J Med 1994; 97 (Suppl 6A): 24S-32S.
4. Andrews JM, Ninan PT, Nemeroff CB. Venlafaxine: a novel antidepressant that has a dual mechanism of action. Depression 1996; 4: 48-56.
5. Ayuso JL, Ballus C, Carrasco JL et al. A multicenter six-month open trial of venlafaxine in major depression. Presented at the meeting of the European College of Neuropsychopharmacology, Vienna, 14-17 September, 1997.
6. Baron BM, Ogden AM, Siegel BW et al. Rapid down-regulation of β-adrenoceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacol 1988; 154: 125-134.
7. Benkert O, Hackett D, Realini R, White C, De Wilde J. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in patients with major depression and melancholia. Neuropsychopharmacology 1994; 10: 165S.
8. Benkert O, Gründer G, Wetzel H, Hackett D. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in patients with major depression and melancholia. J Psychiatr Res 1996; 30: 441-451.
9. Brunello N, Barbaccia ML, Chuang DM et al. Down-regulation of β-adrenergic receptors following repeated injections of desmethylimipramine: permissive role of serotonergic axons. Neuropharmacology 1982; 21: 1145-1149.
10. Clerc GE, Ruimy P, Verdeau-Pailles J, on behalf of the French Inpatient Study Group. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994; 9: 139-143.
11. Cunningham LA, Borison RL, Carman JS et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994; 14: 99-106.
12. Danish University Antidepressant Group. Citalopram. Clinical effect profile in comparison with clomipramine: a controlled multicentre study. Psychopharmacology 1986; 90: 131-138.
13. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disorder 1990; 18: 289-299.
14. Davis JM, Glassman AH. Antidepressant drugs. In: Kaplan HI, Sadock BJ, eds. Comprehensive textbook of psychiatry, 5th edn. Baltimore: Williams and Wilkins, 1989; 2: 1627-1655.
15. de Montigny C. Venlafaxine in treatment-resistant depression. Paper presented at the European College of Neuro-Psychopharmacology, Venice, Italy, September, 1995.
16. Derivan A, Entsuah AR, Kikta D. Venlafaxine: measuring the onset of antidepressant action. Psychopharmacol Bull 1995; 31: 439-447.
17. Derivan AT, Aguiar L, for the Venlafaxine XR 208 Study Group. A double-blind, placebo-controlled comparison of venlafaxine and once-daily venlafaxine in patients with major depression. Presented at the World Congress of Psychiatry, Nice, 23-26 June, 1997.
18. Dierick M. An open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients. Ann Clin Psychiatry 1996; 8: 169-178.
19. Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuro-Psychopharmacol Biol Psychiatry 1996; 20: 57-71.
20. Dornseif BE, Dunlop SR, Potvin JH, Wernicke JF. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull 1989; 25: 71-79.
21. Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. J Clin Psychiatry 1992; 53 (Suppl): 21-26.
22. Ellingrod VL, Perry PJ. Venlafaxine: a heterocyclic antidepressant. Am J Hosp Pharm 1994; 51: 3033-3046.
23. Entsuah AR, Upton GV, Rudolph RL. Efficacy of venlafaxine treatment in depressed patients with psychomotor retardation or agitation: a meta-analysis. Hum Psychopharmacol 1995a; 10: 195-200.
24. Entsuah AR, Rudolph RL, Chitra R. Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients: a meta-analysis. Psychopharmacol Bull 1995b; 31: 759-766.